(IN BRIEF) Boehringer Ingelheim has entered into a global collaboration and licensing agreement with Palatin Technologies to develop melanocortin receptor agonists as a new treatment for retinal diseases, beginning with diabetic retinopathy and diabetic macular edema. The approach targets inflammation, … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged biopharmaceutical collaboration, Boehringer Ingelheim, Carl Spana, diabetic macular edema, diabetic retinopathy, eye health innovation, inflammation, licensing agreement, melanocortin receptor agonists, neurodegeneration, Palatin Technologies, parttnership, Remko Bakker, Retinal Disease Treatment, vascular dysfunction, Vision Preservation, €280 million milestone payments
(IN BRIEF) Roche’s Vabysmo® (faricimab) prefilled syringe has received European Medicines Agency approval for treating three major retinal conditions: neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema caused by retinal vein occlusion (RVO). Serving over nine … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?